NEW YORK (GenomeWeb News) – Maven Biotechnologies is seeking a buyer for its label-free detection and imaging technology.

The technology called LFIRE is a method for detection and ellipsometry reflection and provides enhanced, high-content, label-free detection and imaging and high-capacity screening. Today, BioMed Transition Partners announced Maven Bio has retained its services to help find a buyer for the technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.